William H. Frey, II,Samuel Scott Panter,Leah Ranae Bresin Hanson
申请号：
US14063266
公开号：
US20140179791A1
申请日:
2013.10.25
申请国别(地区):
US
年份:
2014
代理人:
摘要：
Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of progressive supranuclear palsy. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, progressive supranuclear palsy. The effective amount of DFO is delivered directly to the patients central nervous system for preconditioning, preventing and/or treating the progressive supranuclear palsy.
